Abstract

Resistance to first-line treatments for Plasmodium falciparum malaria and the insecticides used for Anopheles vector control are threatening malaria elimination efforts. Suboptimal responses to drugs and insecticides are both spreading geographically and emerging independently and are being seen at increasing intensities. Whilst resistance is unavoidable, its effects can be mitigated through resistance management practices, such as exposing the parasite or vector to more than one selective agent. Resistance contributed to the failure of the 20th century Global Malaria Eradication Programme, and yet the global response to this issue continues to be slow and poorly coordinated—too often, too little, too late. The Malaria Eradication Research Agenda (malERA) Refresh process convened a panel on resistance of both insecticides and antimalarial drugs. This paper outlines developments in the field over the past 5 years, highlights gaps in knowledge, and proposes a research agenda focused on managing resistance. A deeper understanding of the complex biological processes involved and how resistance is selected is needed, together with evidence of its public health impact. Resistance management will require improved use of entomological and parasitological data in decision making, and optimisation of the useful life of new and existing products through careful implementation, combination, and evaluation. A proactive, collaborative approach is needed from basic science and the development of new tools to programme and policy interventions that will ensure that the armamentarium of drugs and insecticides is sufficient to deal with the challenges of malaria control and its elimination.

Highlights

  • Introduction and rationaleOver the past decade, unprecedented progress has been made in reducing malaria morbidity and mortality [1]

  • Growing resistance to the first-line treatment for P. falciparum malaria, artemisinin-based combination therapies (ACTs), and the insecticides used to suppress mosquito vectors threaten the sustainability of recent gains in malaria control and longer-term prospects for elimination

  • This paper aims to review developments in drug and insecticide resistance over the past 5 years (Box 1), discuss gaps in knowledge, and identify key research priorities (Box 2)

Read more

Summary

Introduction

Introduction and rationaleOver the past decade, unprecedented progress has been made in reducing malaria morbidity and mortality [1]. Growing resistance to the first-line treatment for P. falciparum malaria, artemisinin-based combination therapies (ACTs), and the insecticides used to suppress mosquito vectors threaten the sustainability of recent gains in malaria control and longer-term prospects for elimination. Vector control and antimalarial treatment depend on a limited armamentarium, and when single drugs and insecticides are widely deployed, selection pressure is intense and the emergence of resistant parasites and mosquitoes is inevitable. Drug and insecticide resistance were crosscutting issues in the original malERA (Malaria Eradication Research Agenda) series in 2011 [2]. The failure of drug treatment has human consequences: recurrent parasitaemia, severe malaria, anaemia, and associated morbidity and mortality. Resistance to the most widely used class of insecticide, pyrethroids, was first documented in the 1980s, but pyrethroid monotherapies still dominate current control efforts [4]

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call